Waldenstrom macroglobulinemia
Showing 1 - 25 of 503
Waldenstrom Macroglobulinemia Trial in Napoli
Completed
- Waldenstrom Macroglobulinemia
-
Napoli, ItalyUniversity of Naples "Federico II" Naples, Italy, 80100 Contact:
Oct 10, 2023
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial
Not yet recruiting
- Waldenstrom Macroglobulinemia
- +2 more
- (no location specified)
Jul 18, 2023
Waldenström's Macroglobulinemia Trial (zanubrutinib,bendamustine,rituximab)
Not yet recruiting
- Waldenström's Macroglobulinemia
- (no location specified)
Aug 4, 2023
Waldenstrom Macroglobulinemia Trial in Tianjin (Zanubrutinib, Bendamustine and Rituximab)
Recruiting
- Waldenstrom Macroglobulinemia
- Zanubrutinib, Bendamustine and Rituximab
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 13, 2023
Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- B-Cell Lymphoproliferative Disorder
- Pirtobrutinib
- +2 more
-
Boston, Massachusetts
- +2 more
Feb 18, 2023
Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Changchun, China
- +5 more
Jan 27, 2023
Waldenstrom Macroglobulinemia Trial (Venetoclax; Rituximab, DRC)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- Venetoclax; Rituximab
- DRC
- (no location specified)
Nov 4, 2022
Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Chiba, Japan
- +8 more
Jan 27, 2023
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM) Trial in Rochester (Shingrix vaccine)
Completed
- Chronic Lymphocytic Leukemia (CLL)
- Waldenstrom Macroglobulinemia (WM)
- Shingrix vaccine
-
Rochester, New YorkUniversity of Rochester
Jan 9, 2023
B-cell Malignancies Undergoing Treatment With Bruton Tyrosine
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Non-Interventional Study
-
Rochester, MinnesotaMayo Clinic in Rochester
Nov 22, 2023
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +5 more
- Routine care as per site standard.
- (no location specified)
Sep 15, 2023
Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM) Trial in Boston (Prolonged Fasting Intervention,
Not yet recruiting
- Cancer Prevention
- +5 more
- Prolonged Fasting Intervention
- EDUCATION CONTROL
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 28, 2022
Waldenstrom Macroglobulinemia Trial in Canada (Acalabrutinib, Bendamustine, Rituximab)
Recruiting
- Waldenstrom Macroglobulinemia
- Acalabrutinib
- +2 more
-
Calgary, Alberta, Canada
- +8 more
Nov 9, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
-
Boston, MassachusettsDana Farber Cancer Institute
Jun 20, 2022
Waldenström's Macroglobulinemia Trial in Ulm (Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab,
Active, not recruiting
- Waldenström's Macroglobulinemia
- Dexamethasone, Rituximab, Cyclophosphamide
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
-
Ulm, GermanyUniversity Hospital Ulm
May 26, 2022
Waldenstrom Macroglobulinemia, DASATINIB Trial in Boston (Dasatinib)
Recruiting
- Waldenstrom Macroglobulinemia
- DASATINIB
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 22, 2022
Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt
Not yet recruiting
- Relapsed/Refractory Waldenstrom Macroglobulinemia
- +3 more
- Brexucabtagene Autoleucel
- +2 more
- (no location specified)
Sep 8, 2022
Questionnaire and Tissue Banking For Multiple Myeloma,
Active, not recruiting
- Multiple Myeloma
- +3 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 15, 2022
Waldenström's Macroglobulinemia Trial in Busan (Lenalidomide, Bortezomib, Rituximab, Dexamethasone)
Recruiting
- Waldenström's Macroglobulinemia
- Lenalidomide, Bortezomib, Rituximab, Dexamethasone
-
Busan, Sue-gu, Korea, Republic ofKosin University Gospel Hospital
Mar 31, 2022
Clinical, Laboratory and Epidemiologic Characterization of
Recruiting
- Waldenstrom Macroglobulinemia
- +4 more
-
Bethesda, Maryland
- +1 more
Jan 25, 2023